Screener
BridgeBio Pharma BBIO Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.84) | $(0.88) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's other income (expense)?
- BridgeBio Pharma (BBIO) reported other income (expense) of -$60.6M in Q1 2026.
- How has BridgeBio Pharma's other income (expense) changed year-over-year?
- BridgeBio Pharma's other income (expense) increased by 7.1% year-over-year, from -$65.24M to -$60.6M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about BridgeBio Pharma's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude